Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Macrogenics (MGNX) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Macrogenics (MGNX) over the last 14 years, with Q3 2025 value amounting to $3.5 million.

  • Macrogenics' Share-based Compensation fell 4055.28% to $3.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.9 million, marking a year-over-year increase of 158.43%. This contributed to the annual value of $29.4 million for FY2024, which is 6022.97% up from last year.
  • Latest data reveals that Macrogenics reported Share-based Compensation of $3.5 million as of Q3 2025, which was down 4055.28% from $3.7 million recorded in Q2 2025.
  • In the past 5 years, Macrogenics' Share-based Compensation ranged from a high of $11.3 million in Q4 2024 and a low of $3.5 million during Q3 2025
  • Moreover, its 5-year median value for Share-based Compensation was $5.3 million (2022), whereas its average is $5.4 million.
  • In the last 5 years, Macrogenics' Share-based Compensation soared by 15843.08% in 2024 and then tumbled by 4451.96% in 2025.
  • Macrogenics' Share-based Compensation (Quarter) stood at $5.4 million in 2021, then decreased by 12.4% to $4.7 million in 2022, then decreased by 8.06% to $4.4 million in 2023, then soared by 158.43% to $11.3 million in 2024, then tumbled by 68.5% to $3.5 million in 2025.
  • Its Share-based Compensation stands at $3.5 million for Q3 2025, versus $3.7 million for Q2 2025 and $4.4 million for Q1 2025.